RSL1D1 and colorectal neoplasm: In addition to gene silencing, blocking p53- or HDM2-RSL1D1 interaction is another potential treatment strategy for treating p53+/+ colorectal tumors, since overexpression of the RSL1D1-NT or the RSL1D1-CT prevents p53 ubiquitination by competitively inhibiting the formation of the RSL1D1/HDM2/p53 protein complex (Fig. 7).